Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-drug Interaction and Safety of RLD2301 and RLD2007 in Healthy Volunteers
NCT05862090Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2023
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of RLD2301 and RLD2007 in type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve over the dosing interval (AUCtau) and Maximum steady-state plasma concentration (Css,max). Started Apr 2023; status: completed.
02
Drugs
RLD2301RLD2007
03
Conditions
type 2 diabetes mellitus (T2DM)cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT05862090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862090.